FDA approves medicine for treatment of deep vein thrombosis
FDA approves medicine for treatment of deep vein thrombosis
The Food and Drug Administration has approved Janssen Pharmaceuticals, Inc.'s Xarelto (rivaroxaban ). Xarelto is intended for the treatment of deep vein thrombosis (DVT). If all or part of a DVT breaks off, it can travel to and lodge in the lungs, and can lead to potentially life-threatening consequences.
